Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
PluvictoⓇ continued strong performance with improving supply
Sales evolution
Global sales, USD m
80
00
Strong progress in Q2
GROWTH
P
PLUVICTO™
240
Q2 sales of USD 240m, +14% USD vs. Q1
211
179
Millburn (US) and Zaragoza (EU) sites approved for commercial Pluvicto
supply in April, continuing to ramp up gradually
Actively starting new patients and onboarding new centers
Ex-US reimbursement discussions ongoing
Upcoming milestones
PSMAfore pre-taxane data presentation and filing expected in H2
Submission and approval of Indianapolis site (US)
10
2
Q1
Q2
Q3
Q4
Q1
2022
2023
Q2
mCRPC metastatic castration-resistant prostate cancer.
rPFS radiographic progression free survival. OS overall survival.
12 Investor Relations | Q2 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation